Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

Case Studies

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

How Syngene's Green Chemistry initiatives reduced costs by 30% while increasing yield and reducing wastage

Learn how Syngene developed a robust and scalable Green GMP manufacturing process for an oncology drug compound in just eight weeks, which reduced costs by 30%.

How Sygnene delivered more than 90% purity pDNA for a global biotech using a proprietary platform process

Learn how Syngene used its proprietary platform process for pDNA manufacturing from discovery to the clinic to deliver >90% purity pDNA.

How Syngene partnered with a bioengineering company to synthesize a complex, triblock copolymer to address biofouling issues

Learn how Syngene synthesized a complex polymer using the RAFT technique and delivered several kilograms of the polymer in just one month.

How Syngene supported a biotech in developing a PROTAC molecule for treating cancer

Learn how Syngene successfully developed and manufactured several kilograms of a PROTAC molecule under cGMP conditions within 12 months for treating a certain type of cancer.

How Syngene supported a clinical-stage oncology company in manufacturing the RSM for treating a rare tumour

Learn how Syngene reduced the number of steps required to synthesize an RSM for two API candidates by 50% and successfully manufactured and supplied the GMP product to the client.

How Syngene's tech transfer approach helped a biotech company fast-track NDA approval for a novel compound to treat infections

Learn how Syngene ensured 100% first-time-right technology transfer for manufacturing limited number of batches of a novel compound to treat infections, including getting NDA approval in less than two years.

How Syngene screened inhibitors of protein-protein interaction in HTS mode for accelerated drug discovery -image
How Syngene screened inhibitors of protein-protein interaction in HTS mode for accelerated drug discovery

Learn how Syngene screened 50,000 compounds using high throughput screening against two different transcription factors for accelerated drug discovery.

How Syngene accelerated drug discovery against a protein target using HTS-image
How Syngene accelerated drug discovery against a protein target using HTS

Learn how Syngene screened a library of 200,000 compounds using high throughput screening for a single protein target for accelerated drug discovery.

how-syngenes-first-time-right-process-advanced-a-novel-vascular-calcification-inhibitor-api-from-lab-scale-to-tox-batch-manufacturing-successfully
How Syngene's 'first-time right' process advanced a novel vascular calcification inhibitor API from Lab-scale to Tox-batch manufacturing successfully

Learn how Syngene supported a pharma company in developing and manufacturing lab-scale and later Tox batches of its target molecule through an improved synthesis route. All this while meeting chemical purity requirements of >98%.

novel-drug-therapies
How Syngene synthesized a complex cyclic peptide for use in novel drug therapies

Learn how Syngene’s novel approach helped synthesize a complex 11-mer cyclic peptide for use in drug therapies.

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy, Cookies Policy and .

To view or email, Please share your details view

To download, Please share your details